|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-4-14
|
|
pubmed:abstractText |
Placebo-controlled trials have found that angiotensin-converting enzyme inhibitors (ACEIs) decrease proteinuria and slow the progression of nondiabetic nephropathies. However, head-to-head comparisons of ACEIs and calcium channel blockers (CCBs) have shown conflicting results. Indeed, a recent metaanalysis concluded that there is still uncertainty about the greater renoprotection seen with ACEIs or angiotensin II receptor blockers in nondiabetic patients with renal disease, particularly when using true glomerular filtration rate (GFR) as the primary outcome.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0149-2918
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
482-98
|
|
pubmed:meshHeading |
pubmed-meshheading:18405787-Adolescent,
pubmed-meshheading:18405787-Adult,
pubmed-meshheading:18405787-Aged,
pubmed-meshheading:18405787-Aged, 80 and over,
pubmed-meshheading:18405787-Amlodipine,
pubmed-meshheading:18405787-Antihypertensive Agents,
pubmed-meshheading:18405787-Blood Pressure,
pubmed-meshheading:18405787-Cohort Studies,
pubmed-meshheading:18405787-Creatinine,
pubmed-meshheading:18405787-Double-Blind Method,
pubmed-meshheading:18405787-Enalapril,
pubmed-meshheading:18405787-Female,
pubmed-meshheading:18405787-Glomerular Filtration Rate,
pubmed-meshheading:18405787-Humans,
pubmed-meshheading:18405787-Hypertension,
pubmed-meshheading:18405787-Kidney,
pubmed-meshheading:18405787-Kidney Diseases,
pubmed-meshheading:18405787-Male,
pubmed-meshheading:18405787-Middle Aged,
pubmed-meshheading:18405787-Placebos,
pubmed-meshheading:18405787-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
|
|
pubmed:affiliation |
Pasteur Hospital, Université de Nice-Sofia Antipolis, Nice, France. esnault.v@chu-nice.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
